| Drug General Information |
| Drug ID |
D06SYA
|
| Former ID |
DIB000569
|
| Drug Name |
MT-061 lead
|
| Synonyms |
MT-061; Fatty acid biosynthesis inhibitor (Gram positive bacterial infection), MaxThera; MT-061 lead series, Biota; MT-061 lead series, MaxThera
|
| Indication |
Gram-positive bacterial infection [ICD9:]
|
Investigative |
[1]
|
|---|
| Company |
MaxThera Inc
|
| Target and Pathway |
| Target(s) |
Fatty acid synthase |
Target Info |
Inhibitor |
[1]
|
|---|
|
BioCyc Pathway
|
Fatty acid biosynthesis initiation
|
|
Fatty acid elongation -- saturated
|
|
Palmitate biosynthesis
|
|
KEGG Pathway
|
Fatty acid biosynthesis
|
|
Metabolic pathways
|
|
Fatty acid metabolism
|
|
AMPK signaling pathway
|
|
Insulin signaling pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
Validated transcriptional targets of deltaNp63 isoforms
|
|
PathWhiz Pathway
|
Fatty Acid Biosynthesis
|
|
Reactome
|
ChREBP activates metabolic gene expression
|
|
Activation of gene expression by SREBF (SREBP)
|
|
Fatty Acyl-CoA Biosynthesis
|
|
WikiPathways
|
Fatty Acid Biosynthesis
|
|
Nuclear Receptors Meta-Pathway
|
|
Liver X Receptor Pathway
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
SREBP signalling
|
|
Metabolism of water-soluble vitamins and cofactors
|
|
Integration of energy metabolism
|
|
Fatty acid, triacylglycerol, and ketone body metabolism
|
|
AMPK Signaling
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608). |
|---|
